Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 13/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29159241 | 0.98 | VCAM1 (0.53) | VCAM1KDM1AALDH1A1KDM4EPOLB | |
| SCHEMBL15600303 | 0.85 | KDM1A (0.54) | VCAM1KDM1AALDH1A1KDM4EPOLB | |
| SCHEMBL811582 | 0.81 | VCAM1 (0.54) | VCAM1ALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL11307496 | 0.80 | NPC1 (0.52) | VCAM1KDM1AALDH1A1KDM4EPOLB | |
| SCHEMBL1726825 | 0.80 | KDM1A (0.53) | VCAM1KDM1AALDH1A1KDM4EPOLB | |
| SCHEMBL4520586 | 0.79 | VCAM1 (0.53) | VCAM1KDM1AALDH1A1KDM4EPOLB | |
| SCHEMBL13239653 | 0.79 | VCAM1 (0.50) | VCAM1ALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL628112 | 0.78 | PTPRF (0.59) | VCAM1KDM1AALDH1A1MEN1KMT2A | |
| SCHEMBL6255897 | 0.78 | VCAM1 (0.46) | VCAM1KDM1AALDH1A1KDM4EPOLB | |
| SCHEMBL670827 | 0.78 | HPGD (0.51) | VCAM1KDM1AALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| US-20130303571-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303571-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | VCAM1 1862/4885KDM1A 2774/4885ALDH1A1 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.